National Health Act 1953 Amendment Determinations under sections 85, 85A and 88 pharmaceutical benefits (No. PB 51 of 2008) (Cth)

Case

COMMONWEALTH OF AUSTRALIA

Instrument number PB 51 of 2008

Amendment determinations under sections 85, 85A and 88 of the National Health Act 1953

I, DIANA MACDONELL, Acting Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under sections 85, 85A and 88 of the National Health Act 1953.

Dated    1st May           2008

DIANA MACDONELL

Acting Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

Amendment determination — pharmaceutical benefits

1              Commencement

This instrument commences on 1 June 2008.

2              Amendment of PB 89 of 2007

Schedule 1 amends PB 89 of 2007.

Schedule 1        Amendments

  1. Part 1 of Schedule 1, item dealing with Captopril in the forms Tablet 12.5 mg, Tablet 25 mg and Tablet 50 mg

omit from the column headed “Brand”:

Genepharm Limited

and substitute:

Genepharm Pty Ltd

  1. Part 1 of Schedule 1, item dealing with Ciprofloxacin in the forms Tablet 500 mg (as hydrochloride) and


    Tablet 750 mg (as hydrochloride)

omit from the column headed “Brand”:

Genepharm Australasia Limited

and substitute:

Genepharm Pty Ltd

[3]       Part 1 of Schedule 1, item dealing with Citalopram in the form Tablet 20 mg (as hydrobromide)

(a) in the column headed “Brand” insert in alphabetical order:

Celica

(b) omit from the column headed “Brand”:

Citalopram-RL

[4]       Part 1 of Schedule 1, item dealing with Codeine with Paracetamol in the form Tablet containing codeine phosphate 30 mg with paracetamol 500 mg

omit from the column headed “Brand”:

Dymadon Forte

[5]       Part 1 of Schedule 1, after item dealing with Drotrecogin Alfa (activated)

insert in the columns in the order indicated:

Duloxetine

Capsule 30 mg (as hydrochloride)

Capsule 60 mg (as hydrochloride)

Oral

Oral

28

28

..

5

Cymbalta

Cymbalta

[6]       Part 1 of Schedule 1, item dealing with Felodipine in the form Tablet 5 mg (extended release)

omit from the column headed “Brand”:

Felodipine XR 5

and substitute:

Felodil XR 5

[7]       Part 1 of Schedule 1, item dealing with Felodipine in the form Tablet 10 mg (extended release)

omit from the column headed “Brand”:

Felodipine XR 10

and substitute:

Felodil XR 10

[8]       Part 1 of Schedule 1, item dealing with Flucloxacillin

omit from the columns in the order indicated:

Powder for oral suspension 125 mg (as magnesium) per
5 mL, 100 mL
Oral 1 .. Floxapen

[9]       Part 1 of Schedule 1, item dealing with Gabapentin in the form Tablet 600 mg

omit from the column headed “Brand”:

Pharmacor Gabapentin 600

[10]     Part 1 of Schedule 1, item dealing with Gabapentin in the form Tablet 800 mg

omit from the column headed “Brand”:

Pharmacor Gabapentin 800

[11]     Part 1 of Schedule 1, after item dealing with Glucose Indicator—Blood in the form Electrode strips, 50 (TrueTrack)

insert in the columns in the order indicated:

Electrode strips, 100 (FreeStyle Lite) For external use 1 5 FreeStyle Lite

[12]     Part 1 of Schedule 1, item dealing with Hydrochlorothiazide with Amiloride

omit from the column headed “Brand”:

Amizide

[13]     Part 1 of Schedule 1, item dealing with Meloxicam in the form Tablet 7.5 mg

in the column headed “Brand” insert in alphabetical order:

Meloxicam Winthrop

[14]     Part 1 of Schedule 1, item dealing with Meloxicam in the form Tablet 15 mg

in the column headed “Brand” insert in alphabetical order:

Meloxicam Winthrop

[15]     Part 1 of Schedule 1, item dealing with Metformin in the forms Tablet containing metformin hydrochloride 500 mg and Tablet containing metformin hydrochloride 850 mg

omit from the column headed “Brand”:

Genepharm Australasia Limited

and substitute:

Genepharm Pty Ltd

[16]     Part 1 of Schedule 1, item dealing with Norfloxacin

omit from the column headed “Brand”:

Genepharm Limited

and substitute:

Genepharm Pty Ltd

[17]     Part 1 of Schedule 1, item dealing with Oxaliplatin in the form Powder for I.V. infusion 50 mg

omit from the column headed “Brand”:

Oxaliplan 50

[18]     Part 1 of Schedule 1, item dealing with Oxaliplatin in the form Powder for I.V. infusion 100 mg

omit from the column headed “Brand”:

Oxaliplan 100

[19]     Part 1 of Schedule 1, after item dealing with Potassium Chloride with Potassium Bicarbonate

insert in the columns in the order indicated:

Pramipexole

Tablet containing pramipexole hydrochloride
125 micrograms

Tablet containing pramipexole hydrochloride
250 micrograms

Tablet containing pramipexole hydrochloride 1 mg

Oral

Oral

Oral

30

100

100

..

5

5

Sifrol

Sifrol

Sifrol

[20]     Part 1 of Schedule 1, item dealing with Pravastatin in the form Tablet containing pravastatin sodium 10 mg

omit from the column headed “Brand”:

Pravastatin-RL

[21]     Part 1 of Schedule 1, item dealing with Pravastatin in the form Tablet containing pravastatin sodium 20 mg

omit from the column headed “Brand”:

Pravastatin-RL

[22]     Part 1 of Schedule 1, item dealing with Pravastatin in the form Tablet containing pravastatin sodium 40 mg

omit from the column headed “Brand”:

Pravastatin-RL

[23]     Part 1 of Schedule 1, item dealing with Quinapril in the form Tablet 20 mg (as hydrochloride)

in the column headed “Brand” insert in alphabetical order:

Quinapril Sandoz

[24]     Part 1 of Schedule 1, item dealing with Roxithromycin in the form Tablet 150 mg

omit from the column headed “Brand”:

Roxithromycin-RL

[25]     Part 1 of Schedule 1, item dealing with Roxithromycin in the form Tablet 300 mg

omit from the column headed “Brand”:

Roxithromycin-RL

[26]     Part 1 of Schedule 1, item dealing with Simvastatin in the form Tablet 5 mg

omit from the column headed “Brand”:

Simvastatin-RL

[27]     Part 1 of Schedule 1, item dealing with Simvastatin in the form Tablet 10 mg

(a) omit from the column headed “Brand”:

Genepharm Australasia Limited

and substitute:

Genepharm Pty Ltd

(b) omit from the column headed “Brand”:

Simvastatin-RL

[28]     Part 1 of Schedule 1, item dealing with Simvastatin in the form Tablet 20 mg

(a) omit from the column headed “Brand”:

Genepharm Australasia Limited

and substitute:

Genepharm Pty Ltd

(b) omit from the column headed “Brand”:

Simvastatin-RL

[29]     Part 1 of Schedule 1, item dealing with Simvastatin in the form Tablet 40 mg

(a) omit from the column headed “Brand”:

Genepharm Australasia Limited

and substitute:

Genepharm Pty Ltd

(b) omit from the column headed “Brand”:

Simvastatin-RL

[30]     Part 1 of Schedule 1, item dealing with Simvastatin in the form Tablet 80 mg

(a) omit from the column headed “Brand”:

Genepharm Australasia Limited

and substitute:

Genepharm Pty Ltd

(b) omit from the column headed “Brand”:

Simvastatin-RL

[31]     Part 2 of Schedule 1, item dealing with Codeine with Paracetamol in the form Tablet containing codeine phosphate 30 mg with paracetamol 500 mg

omit from the column headed “Brand”:

Dymadon Forte

[32]     Part 1 of Schedule 3, item dealing with Codeine with Paracetamol in the form Tablet containing codeine phosphate 30 mg with paracetamol 500 mg

omit from the column headed “Brand”:

Dymadon Forte

[33]     Part 1 of Schedule 3, item dealing with Flucloxacillin

omit from the columns in the order indicated:

Powder for oral suspension 125 mg (as magnesium) per
5 mL, 100 mL
Oral 1 .. Floxapen
Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0